Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Investor Day. While these events are often catalysts for stock, ...

We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

Moderna Inc. aims to reduce its research and development budget by about 20% over the next three years as the biotech tries ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...

Human papillomavirus (virus like particle, 9-valent) vaccine is under clinical development by Merck and currently in Phase II for Human Papillomavirus Infections.

In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar potential: It holds a first-mover advantage in one of the largest cancer indications of non-small cell lung ...